Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells

  • Alexander V. Aksenov
  • , Alexander N. Smirnov
  • , Igor V. Magedov
  • , Mary R. Reisenauer
  • , Nicolai A. Aksenov
  • , Inna V. Aksenova
  • , Alexander L. Pendleton
  • , Gina Nguyen
  • , Robert K. Johnston
  • , Michael Rubin
  • , Annelise De Carvalho
  • , Robert Kiss
  • , Véronique Mathieu
  • , Florence Lefranc
  • , Jaime Correa
  • , David A. Cavazos
  • , Andrew J. Brenner
  • , Brad A. Bryan
  • , Snezna Rogelj
  • , Alexander Kornienko
  • Liliya V. Frolova

Producción científica: Article › revisión exhaustiva

Resumen

Many types of tumor, including glioma, melanoma, non-small cell lung, esophageal, and head and neck cancer, among others, are intrinsically resistant to apoptosis induction and poorly responsive to current therapies with proapoptotic agents. In addition, tumors often develop multidrug resistance based on the cellular efflux of chemotherapeutic agents. Thus, novel anticancer agents capable of overcoming these intrinsic or developed tumor resistance mechanisms are urgently needed. We describe a series of 2-aryl-2-(3-indolyl)acetohydroxamic acids that are active against apoptosis-and multidrug-resistant cancer cells as well as glioblastoma neurosphere stemlike cell cultures derived from patients. Thus, the described compounds serve as a novel chemical scaffold for the development of potentially highly effective clinical cancer drugs.

Idioma originalEnglish (US)
Páginas (desde-hasta)2206-2220
Número de páginas15
PublicaciónJournal of Medicinal Chemistry
Volumen58
N.º5
DOI
EstadoPublished - mar 12 2015

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Huella

Profundice en los temas de investigación de 'Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells'. En conjunto forman una huella única.

Citar esto